Anti-Kickback Statute

Latest Headlines

Latest Headlines

Former gynecologist accused of taking pharma kickbacks says she was unfairly targeted

A former Massachusetts gynecologist accused of taking kickbacks from Warner Chilcott says she was targeted by federal officials because she is an Indian woman, according to  MassLive.com.  

Addiction treatment initiatives won't succeed without a closer eye on fraud

President Obama is poised to announce new addiction treatment initiatives, adding to the $1.1 billion he proposed earlier this year to improve access to treatment services. While improving access to addiction treatment is laudable, the corrupt underbelly of the industry that preys on the vulnerabilities of addicts offers a barrier to successfully implementing new approaches to care. Failure to address these fraudulent practices will negate the impact of any new approaches to addiction treatment, offering a larger cash grab for fraudsters, and making an already defenseless patient population even more vulnerable.  

Sleep apnea mask manufacturer pays $34M to settle kickback allegations

A Pennsylvania manufacturer that specializes in sleep apnea masks has agreed to pay $34.8 million to settle allegations it offered free services to durable medical equipment suppliers to incentivize increased equipment sales, according to the Department of Justice.  

How a massive kickback scheme eroded Olympus' corporate culture

In 2012, Olympus warned European hospitals that one of its medical scopes was harboring dangerous bacteria. More than two years later, U.S. hospitals reported infectious outbreaks linked to the same scope that ultimate infected more than 250 people between 2012 and 2015. The patient safety debacle left many wondering how this could happen. A massive kickback scheme that predated the outbreak offers some belated clues, revealing an eroded corporate culture that valued profits over compliance, regardless of the repercussions.

Fierce Exclusive: After explosion of compounded drug fraud, legal experts say party's over

In April 2015, Tricare spent $545 million on compounded pharmaceuticals, more than 58 times its monthly spending just three years prior. The spike in spending marked the peak of a gradual increase in spending on compound drugs that accelerated during the first several months of 2015 as Tricare was initiating changes to its pharmaceutical formulary. Now, federal investigators are digging into pharmacies that may have relied on marketers to generate referrals, while shielding the true effectiveness and cost of compounded medications.  

Olympus pays $646M to settle kickback allegations

The nation's largest distributor of endoscopes has agreed to pay $646 million to settle criminal and civil claims that the company offered various kickbacks to hospitals and doctors that signed deals to purchase medical equipment, according to the Department of Justice.  

Legislators take aim at Stark law in light of value-based payment changes

Legislators are asking industry stakeholders for input regarding potential changes to. Stark law in light of the ongoing transition towards value-based payments, according to a report by Bloomberg BNA.

PharMerica and the terrible, horrible, no good, very bad year

Last year was a terrible, horrible, no good, very bad year for PharMerica Corp., the second largest pharmacy operator in the country that ended up spending $43.25 million to resolve multiple False Claims Act allegations from the federal government. In the span of 12 months, the company negotiated multi-million dollar settlements and entered into another corporate integrity agreement for accepting kickbacks and illegally dispensing drugs. 

Memorial Health pays $9.8 million in record False Claims Act lawsuit

Memorial Health, Inc. will pay $9.8 million to settle False Claims Act allegations in the largest civil healthcare fraud recovery ever recorded by the U.S. Attorney's Office for the Southern District of Georgia.  

Public-private partnerships critical in $390M Novartis settlement

A collaborative effort that included both public and private legal teams was a critical element in forcing Novartis into a $390 million settlement finalized last month, according to a  Bloomberg BNA  Q&A with one of the whistleblower attorneys involved in the case.